THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014
- Arix co-leads a $63 million Series B investment in new portfolio company Imara
- Arix commits $15.0 million (£11.3 million) for 10% ownership stake
- Arix expands breadth of portfolio with investment in sickle cell disease via a later-stage clinical asset in phase 2
LONDON, 18 March 2019: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. (“Imara”), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease (“SCD”) and other hemoglobinopathies.